Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy

Giuseppe Lapadula, Carlo Torti, Giuseppe Paraninfo, Filippo Castelnuovo, Maria Cristina Uccelli, Silvia Costarelli, Nicoletta Ladisa, Renato Maserati, Massimo Di Pietro, Annalisa De Silvestri, Carmine Tinelli, Massimo Puoti, Giampiero Carosi

Research output: Contribution to journalArticle

Abstract

Background: The independent role of HCV genotype 3 (HCV-3) in dyslipidaemia following highly active antiretroviral therapy (HAART) is still unexplored. Methods: Analysis of data from a cohort of 307 HIV/HCV-coinfected patients and 415 HIV-monoinfected controls was conducted. Patients with available lipid levels at baseline and minimum 3-month follow-up were ranked into three groups by HCV status (HCV-3, other HCV genotypes or HCV negative). Univariate and multivariate GEE models were performed to assess factors correlated with lipid serum levels as coefficient (Coef., defined as mean difference [mg/dl] across the follow-up). Univariate and multivariate logistic regression analyses were performed for prediction of relevant hypertriglyceridaemia (≥500 mg/dl) and relevant hypercholesterolaemia (≥240 mg/dl) at 3 months of follow-up. Results: HCV-3 correlated with lower triglyceridaemia (Coef.=-38.22; P=0.001), independently from the other considered variables, including age, gender and use of stavudine or lopinavir. Even though HCV infection per se appeared to be protective, HCV-3 in particular was also independently associated with lower cholesterolaemia (Coef.=-46.35; P

Original languageEnglish
Pages (from-to)521-527
Number of pages7
JournalAntiviral Therapy
Volume11
Issue number4
Publication statusPublished - 2006

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology

Cite this

Lapadula, G., Torti, C., Paraninfo, G., Castelnuovo, F., Uccelli, M. C., Costarelli, S., Ladisa, N., Maserati, R., Di Pietro, M., De Silvestri, A., Tinelli, C., Puoti, M., & Carosi, G. (2006). Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antiviral Therapy, 11(4), 521-527.